Related Experiment Video

Updated: Feb 27, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K

Trop2-Based Antibody-Drug Conjugates: Emerging Strategy and Progress in Triple-Negative Breast Cancer Therapy

Tong Li1, Tao Zhang2, Yongxia Dang1

  • 1The First Clinical Medical College, Lanzhou University, No. 199 Donggang West Road, Lanzhou 730000, China.

Current Oncology (Toronto, Ont.)
|February 26, 2026
PubMed

Insights

Triple-negative breast cancer (TNBC) is aggressive with few treatments. Trop2-targeted antibody-drug conjugates (ADCs) show promise for improving outcomes in TNBC patients by targeting Trop2-overexpressing tumors.

Area of Science:

  • Oncology
  • Translational Medicine
  • Drug Development

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive cancer subtype with limited therapeutic strategies.
  • Trophoblast cell-surface antigen 2 (Trop2) is overexpressed in TNBC (88% of cases) and linked to poor prognosis.
  • Trop2 overexpression correlates with tumor invasion and metastasis.

Purpose of the Study:

  • To review the clinical progress of Trop2-targeted antibody-drug conjugates (ADCs) for TNBC.
  • To provide evidence-based insights for enhancing TNBC patient outcomes.

Main Methods:

  • Systematic review of clinical research on Trop2-targeted ADCs.
  • Analysis of Trop2 expression in TNBC and normal tissues.
  • Evaluation of Trop2-ADC clinical trial data.

Main Results:

  • Trop2 is a promising therapeutic target due to its high expression in TNBC and low expression in normal tissues.
  • Trop2-targeted ADCs have shown significant clinical potential in treating TNBC.
  • ADC efficacy is linked to Trop2 expression levels and tumor characteristics.

Conclusions:

  • Trop2-targeted ADCs represent a promising therapeutic avenue for TNBC.
  • Further research and clinical trials are needed to optimize ADC therapy for TNBC.
  • Targeting Trop2 may improve clinical outcomes for patients with this aggressive cancer subtype.
Keywords:
Trophoblast cell-surface antigen 2 (Trop2)antibody–drug conjugates (ADCs)clinical researchtargeted therapytriple-negative breast cancer (TNBC)

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.0K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K